Medidata and Pharm-Olam International have signed a new, five-year enterprise agreement to unify operational systems supporting study execution on Medidata Cloud.

Pharm-Olam previously used multiple systems and vendors, which led to duplicate data and silos requiring later integration. With Medidata, the global contract research organisation (CRO) will empower sponsors to accelerate drug therapy time to market by providing a single, unified view of clinical trials to all stakeholders.

“After an exhaustive search, we selected Medidata because only their platform can unify all of our data and empower us to leapfrog the competition,” said David L. Grange, CEO, Pharm-Olam. “By leveraging Medidata’s best-in-class technology, we will reduce costs and provide superior solutions to our customers.”

“We’re thrilled to expand our strategic partnership and help Pharm-Olam drive digital transformation for their customers,” said Glen de Vries, president and co-founder, Medidata. “For CROs and sponsors of all sizes, our unified platform enables faster, better decision making that accelerates research and the delivery of life-changing therapies to patients.”